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Background: Osteoarthritis (OA) is a common health issue worldwide in the aging population who are also
commonly deficient in vitamin D. Our previous study suggested that higher serum 25-(OH)D levels were associated
with reduced knee cartilage loss, implying that vitamin D supplementation may prevent the progression of knee
OA. The aim of the VItamin D Effects on OA (VIDEO) study is to compare, over a 2- year period, the effects of
vitamin D supplementation versus placebo on knee structural changes, knee pain, and lower limb muscle strength
in patients with symptomatic knee OA.
Methods/design: Randomised, placebo-controlled, and double-blind clinical trial aiming to recruit 400 subjects
(200 from Tasmania and 200 from Victoria) with both symptomatic knee OA and vitamin D deficiency
(serum [25-(OH)D] level of >12.5 nmol/liter and <60 nmol/liter). Participants will be randomly allocated to vitamin D
supplementation (50,000 IU compounded vitamin D3 capsule monthly) or identical inert placebo group for 2 years.
The primary endpoint is loss of knee cartilage volume measured by magnetic resonance imaging (MRI) and
Western Ontario and McMaster Universities Index of OA (WOMAC) knee pain score. The secondary endpoints will
be other knee structural changes, and lower limb muscle strength. Several other outcome measures including core
muscle images and central blood pressure will be recorded. Linear and logistic regression will be used to compare
changes between groups using univariable and multivariable modeling analyses. Both intention to treat and per
protocol analyses will be utilized.
Discussion: The trial is designed to test if vitamin D supplementation will reduce loss of knee cartilage volume,
prevent the progression of other knee structural abnormalities, reduce knee pain and strengthen lower limb muscle
strength, thus modify disease progression in knee OA.
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Osteoarthritis (OA) is the most common form of arth-
ritis in the world and one of the most common chronic
conditions managed in Australian general practice [1,2].
It is characterized by the gradual loss of articular cartil-
age and changes to other joint structures eventually
leading to total joint replacement. Currently there is no
cure for OA, and the development of innovative and
cost-effective approaches to prevent the development
and progression of OA is urgent and important.
Vitamin D comprises a group of fat-soluble secoster-
oids emcompassing two major molecules, vitamin D2
and vitamin D3. Vitamin D is circulated to the liver
where it is converted to the prohormone calcidiol, or
25-hydroxy-vitamin D (25-(OH)D), which is the best in-
dicator of vitamin D status [3-5]. Vitamin D deficiency is
very common in older people. It is estimated that 20 to
100% of elderly men and women in North America and
Europe are vitamin D deficient (mostly defined as a
serum level of 25-(OH)D< 50 nmol/liter)[6,7]. High rates
of vitamin D deficiency have also been reported in all
sectors of the community of Australia, especially in
Tasmania and Victoria where this study will be con-
ducted [8-10].
It has been widely recognized that OA is a disease
affecting the whole joint, including cartilage, bone and
muscle. Through targeting these joint tissues vitamin D
supplementation may modify disease progression in OA.
Vitamin D receptors (VDRs) are found in human articu-
lar chondrocytes [11], and 1α-25(OH)2D3 regulates the
expression of metalloproteinase (MMP) and prostaglan-
din E2 (PGE2) in chondrocytes via VDRs [11]. Vitamin D
could enhance the ability of bone to respond optimally
to pathophysiological processes in OA, thus prevent dis-
ease progression [12,13]. Furthermore, 1,25(OH)2D leads
to de novo protein synthesis, muscle cell growth, and
improved muscle function, and thus has a beneficial
effect on muscle strength [14].
Epidemiological studies have provided preliminary
evidence supporting the potential use of vitamin D for
the treatment of OA. Lower serum levels of 25-(OH)D
were associated with greater knee pain [15] and higher
prevalence of radiographic OA [16], and predicted inci-
dence of knee pain [17], progression/incidence of radio-
graphic OA [18,19], and loss of joint space, as well as
osteophyte growth [18]. Magnetic resonance imaging
(MRI) has been utilized to directly assess knee struc-
tural alterations such as cartilage volume, cartilage
defects, subchondral bone changes and meniscal lesions.
Using MRI, we reported that, in cross-sectional analysis,
serum 25-(OH)D level was significantly and positively
associated with knee cartilage volume in older men and
women, and vitamin D insufficiency was positively asso-
ciated with medial and lateral tibial bone area inwomen. Longitudinally, higher baseline serum levels of
25-(OH)D predicted reduced loss of cartilage volume
over 2 years, and increases in vitamin D levels were
associated with further protective association [15,16].
Furthermore, serum levels of 25-(OH)D were also asso-
ciated with increased leg muscle strength and quality,
and thus may be important for the maintenance of
muscle function [20].
Based on this experimental and epidemiological evi-
dence, we have initiated a randomized, placebo-
controlled trial (Vitamin D Effect on Osteoarthritis,
VIDEO study) to determine if vitamin D supplementa-
tion can reduce loss of knee cartilage volume, prevent
the progression of other knee structural abnormalities
and strengthen lower limb muscle strength, and thus
modify disease progression in knee OA. The effects of
vitamin D supplementation on the progression of knee
pain will also be determined.
In a sub-study, we will examine the effects of vitamin
D supplementation on the function of deep lumbo-pelvic
stabilising muscles. The protective deep lumbo-pelvic
stabilising muscles, which include (but not exclusively)
the transversus abdominus (TrAb) and lumbar multifidus
and which are known as core muscles, become dysfunc-
tional shortly after the onset of low back pain, and that
ongoing muscle dysfunction is associated with persistent
low back pain [18,21]. Muscle weakness can be a sign of
vitamin D deficiency [19] and therefore, vitamin D sup-
plementation may have beneficial effects on functionally
important core muscles.
Furthermore, we will determine the effect of vitamin
D supplementation on blood pressure (clinical, ambula-
tory, upper arm and central measures) and arterial stiff-
ness (aortic pulse wave velocity). Several lines of
evidence suggest that vitamin D deficiency may influ-
ence blood pressure via mechanisms including activation
of the renin-angiotensin-aldosterone system (RAAS)
[22-24]. Central and ambulatory blood pressure will be
the main outcomes because central blood pressure is the
actual pressure load experienced by the heart (and other
organs such as the kidneys and brain) rather than the
pressure at the upper arm [25], and ambulatory blood
pressure is regarded as the gold standard technique be-
cause it correlates with target organ damage and pro-
vides more accurate information on daily (including
night time) blood pressure fluctuations [26].
Methods/design
Study design
VIDEO is a randomized, placebo-controlled double-blind
clinical trial. Four hundred subjects (200 from Tasmania
and 200 from Victoria) with symptomatic knee OA and
serum 25-(OH)D> 12.5 nmol/liter and < 60 nmol/liter
will be recruited and randomly allocated to either the
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ods will include advertisements through the local media
and community groups as well as liaisons with general
practitioners, specialist rheumatologists, and orthopedic
surgeons. Ethics approval has been received from The
Tasmania Health and Human Medical Research Ethics
Committee (reference number H1040) and Monash Uni-
versity Human Research Ethics Committee (reference
number CF10/1182 - 2010000616). Informed written
consent will be obtained from all participants.
Inclusion criteria
The inclusion criteria were as follows: age 50 to 79 years;
symptomatic knee OA for at least 6 months with a pain
at least 20 mm on a 100 mm visual analogue scale
(VAS); American College of Rheumatology (ACR) cri-
teria for symptomatic knee OA assessed by a rheuma-
tologist [27]; ACR functional class rating of I, II and III
[28]; relatively good health, with a score of 0 to 2 on a 5-
point Likert scale (with a range of 0 indicating very good
health to 4 indicating very poor health), according to the
investigators global assessment of disease status; serum
25-(OHD)D> 12.5 nmol/liter and < 60 nmol/liter; able to
read, speak and understand English, capable of under-
standing the study requirements and willing to cooper-
ate with the study instructions.
Exclusion criteria
Exclusion criteria were as follows: severe radiographic
knee OA, grade 3 according to Altman’s atlas [29]; severe
knee pain on standing (more than 80 mm on 100-mm
VAS); any contraindication to having MRI; rheumatoid or
psoriatic arthritis, lupus or cancer; severe cardiac or renal
impairment; hypersensitivity to vitamin D; any condition
possibly affecting oral drug absorption (for example, gas-
trectomy or malabsorption syndromes); significant trauma
to knees, including arthroscopy or significant injury to
ligaments or menisci of the knee within one preceding the
study; anticipated need for knee or hip surgery within the
next 2 years; history of taking vitamin D supplements
within the previous 30 days; history of taking an investiga-
tional drug within the previous 30 days.
Randomization
Participants in each site will be randomly assigned to the
intervention arm or placebo arm in a ratio of 1:1 and
the randomization will be double-blind. Allocation of
participants will be based on computer-generated ran-
dom numbers. Allocation concealment will be ensured
by the use of an identical inert placebo, and a central
automated allocation procedure, with security in place
to ensure allocation data cannot be accessed or influ-
enced by any person.Intervention
Participants in the intervention arm will take one cap-
sule per month of 50,000 IU (1.25 mg) of a vitamin D3
compound (cholecalciferol), purchased from Nationwide
Compounding Pharmacy, Melbourne, Australia[30], and
patients in the control arm will receive an identical inert
placebo provided by the same company. Patients are
required to record their medication information in per-
sonal diaries and a reminder will be given each month.
All participants will receive the recommended standard
of care. The duration of the study is 2 years.
Quality assurance
To ensure that this trial will be of a high standard and
delivered in accordance with the trial protocol, all re-
search staff will be provided with a standard protocol
and case report form, and will be trained to competently
administer items as per protocol. The investigators, re-
search assistants and outcome assessors are different
people. Protocols will not be altered during the study
timeframe.
Outcome measures
The co-primary efficacy endpoints of the study will be
MRI assessment of volume changes in knee cartilage
from baseline to month 24, as well as the Western On-
tario and McMaster Universities Index of OA
(WOMAC) score [31] (Table 1). The secondary end-
points will be other knee structural changes (cartilage
defects, tibial plateau bone area, and bone marrow
lesions, meniscal tear and extrusion) from baseline to
month 24, and lower limb muscle strength at months 3,
6, 12 and 24 (Table 1).
MRI assessment of knee structural changes
Knees will be imaged in the sagittal plane on a 1.5-T
whole body MRI unit using a commercial transmit-
receive extremity coil. Fat-saturated T1-weighted spoiled
gradient echo (GRE) and T2-weighted/proton density-
weighted fast spin echo (FSE) sequences will be used.
The images will be assessed by two readers blinded to
the treatment according to the methods described in our
previous publications [15,32].
Cartilage volume: the volumes of individual cartilage
plates (medial tibial, lateral tibial and patella) are isolated
from the total volume by manually drawing disarticula-
tion contours around the cartilage boundaries on a
section-by-section basis. Sagittal images will be obtained
at a partition thickness of 1.5 mm and an in-plane reso-
lution of 0.31 × 0.31 mm (512 × 512 pixels), then
resampled by means of bilinear and cubic interpolation
(area of 312 μm×312 μm and multiplied by 1.5 mm
thickness, continuous sections) for the final 3D render-
ing. Particular cartilage volume was then determined by
Table 1 Timetable and measures to be made
Screening Month(s)
0 3 6 12 24
Co-primary outcome measure
MRI (cartilage volume changes) ✓ ✓
WOMAC ✓ ✓ ✓ ✓ ✓
Secondary outcome measure
MRI (other structural changes) ✓ ✓
Lower limb muscle strength ✓ ✓ ✓ ✓ ✓
Other measures
Core musculature measure ✓ ✓ ✓
Hand grip strength ✓ ✓ ✓ ✓ ✓
Central and upper arm blood pressure ✓ ✓ ✓ ✓
Aortic stiffness ✓ ✓ ✓ ✓
Physical activity (IPAQ) ✓ ✓
Body fat ✓ ✓ ✓
Low foot pain ✓ ✓ ✓ ✓ ✓
Low back pain ✓ ✓ ✓ ✓
Depression ✓ ✓ ✓ ✓ ✓
Quality of life ✓ ✓ ✓ ✓
Previous knee injury and occupation ✓ ✓
Weight ✓ ✓ ✓ ✓ ✓
Height ✓ ✓
Girth measurements ✓ ✓ ✓
Knee radiograph ✓
Serum 25-(OH)D ✓ ✓ ✓
Serum calcium, phosphate, creatinine ✓ ✓
Sun exposure ✓ ✓ ✓ ✓
Cigarette smoking ✓ ✓
Diet (FFQ) and pedometer ✓ ✓
Medications ✓ ✓ ✓ ✓ ✓ ✓
Pill counts and adverse events ✓ ✓ ✓ ✓ ✓
Participants who withdraw within one year will be asked to have MRI at
month 12; patients who withdraw after one year will be asked to have MRI
straight away. MRI: magnetic resonance imaging; WOMAC: Western Ontario
McMaster Universities Osteoarthritis Index; 25-(OHD)D: 25-hydroxy-vitamin D;
FFQ: food frequency questionnaire.
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Cartilage defects assessment: the cartilage defects (0 to
4) will be graded at medial tibial and femoral, lateral tib-
ial and femoral, and patellar sites: grade 0, normal cartil-
age; grade 1, focal blistering and intracartilaginous low-
signal intensity area with an intact surface and bottom;
grade 2, irregularities on the surface or bottom and loss
of thickness of less than 50%; grade 3, deep ulceration
with loss of thickness of more than 50%; grade 4, full-
thickness chondral wear with exposure of subchondral
bone.Knee tibial plateau bone area: the area of the medial
and lateral tibial plateau bone will be measured manually
on the three reformatted images closest to the tibial car-
tilage. An average of these three areas will be used as an
estimate of the tibial plateau bone area.
Subchondral bone marrow lesions: This will be
assessed on the T2-weighted MRI and defined as discrete
areas of increased signal adjacent to the subcortical bone
at the lateral, medial femur and/or tibia. Each bone mar-
row lesion will be scored on the basis of lesion size, for
example, a lesion is scored as grade 1 if it occupies < 25%
of the region; grade 2 if it occupies 25% to 50% of the re-
gion; or grade 3 if it occupies > 50% of the region.
Meniscal tear assessment: the menisci will be assessed
in the sagittal view and confirmed in the coronal and
axial views as previously described [33]. In brief, the
presence or absence of a tear is based on the presence of
a signal, which is line shaped, brighter than the dark me-
niscus, and reaches the surface of the meniscus at both
ends within six defined regions (anterior horn, body, and
posterior horn at both medial and lateral tibiofemoral
compartments).
Mensical extrusion assessment: the extent of meniscal
extrusion on the medial or lateral edges of the tibial fem-
oral joint space for the anterior, body, and posterior
horns of the menisci will be graded, where a score of
0 = no extrusion, 1 = partial meniscal extrusion, and
2 = complete meniscal extrusion with no contact with the
joint space.
Lower limb muscle strength
This will be measured by dynamometry (TTM Muscle
Meter, Tokyo, Japan) at the lower limb (involving both
legs simultaneously). The muscles measured with this
technique are mainly the quadriceps and hip flexors.
The device will be calibrated by suspending known
weights at regular intervals.
WOMAC
Knee pain will be assessed by both WOMAC pain sub-
scale (walking on a flat surface, going up/down stairs, at
night in the bed , sitting/lying and standing upright) and
a 100 mm VAS.
Other measurements
Core musculature measure: Core muscle images will be
taken at baseline and 12 months. Images of the core
muscles (TrAb, internal oblique muscles and LM) are
taken with real-time dynamic ultrasound using a fully
featured big box diagnostic ultrasound machine (Phillips
HDI 5000, Bothell, WA, US) with a hand held 7.5 mHz
linear array transducer. Images are taken of right and left
sides, both at rest and during contraction (drawing in of
abdomen) using previously published protocols [34,35].
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interclass correlation coefficient (ICC) > 0.90 across a
range of studies [36].
Upper arm blood pressure, central blood pressure and
aortic stiffness: Clinical upper arm blood pressure will be
measured twice after 5 minutes seated rest using a vali-
dated device (Omron HEM-907, Kyoto, Japan). Seated
clinical central blood pressure will be recorded (immedi-
ately after upper arm blood pressure) using radial appla-
nation tonometry (SphygmoCor 8.1, AtCor Medical,
Sydney, Australia). Aortic stiffness will be measured by
electrocardiogram-gated, sequential carotid to femoral
pulse wave velocity as per expert consensus [37].
Physical activity: Physical activity will primarily be
assessed using a pedometer (SW 200 Digi-Walker,
Yamax Corporation, Tokyo, Japan), which measures ver-
tical displacement (steps per day). The pedometer will
be worn for seven consecutive days on two occasions
(baseline and 2 years) as up to seven days is required to
accurately assess habitual physical activity [38]. We
will also measure physical activity using the Inter-
national Physical Activity Questionnaire (IPAQ) short
version [39].
Body fat: Body fat will be assessed using bioelectrical
impedance analysis (BIA) (BIA analyser, Quantum II,
RJL Systems, Michigan, USA). Fat-free mass, % fat-free
mass, fat mass and % fat mass will be assessed [40].
Hand grip strength: Hand grip strength will be
assessed to the nearest kg in both the right and left hand
using a hydraulic hand dynamometer (Saehan Corpor-
ation, Masan, Korea). Both hands will be alternately
measured in triplicate.
Radiographic OA: this will be assessed at baseline by a
standing semiflexed anterior-posterior (AP) radiograph
as per the Altman atlas [29]. Radiographs will also be
assessed simultaneously by two observers using the
Osteoarthritis Research Society International (OARSI)
atlas to score osteophytes and joint space narrowing on
a four-point scale (0 to 3).
Laboratory measurements: serum 25-(OH)D will be
assayed at month 0, 3 and 24, utilizing a Liquid Phase
radioimmunoassay (Immunodiagnostics Systems Ltd,
Boldon, Tyne & Wear, UK). Serum calcium, phosphate
and renal function will be assessed at month 0 and 3
using routine biochemical methods.
Anthropometrics and other questionnaires: Height will
be measured to the nearest 0.1 cm (with shoes removed)
using a stadiometer (Leicester Height Measure, Invicta
Plastics Ltd, Leicester, UK). Weight will be measured to
the nearest 0.1 kg (with shoes and bulky clothing
removed) using electronic scales (Heine S-7307, Heine,
New Hampshire, USA). Waist and hip measurements
will be assessed using a tape measure to the nearest
0.1 cm (Figure Finder Tape Measure, Novel ProductsInc, Illinois, USA). Sun exposure, employment status
and occupation, depression, smoking status, previous
knee injury, dietary intake, low back and foot pain and
quality of life will be assessed by questionnaires.Safety assessments
Spontaneously reported adverse events will be recorded
throughout the study. Intensity and relationship with the
study medication will be ascribed.Sample size
All sample size calculations assume α= 0.05 and β= 0.20
and are performed based upon formulae provided by
Cohen [41]. Table 2 describes the sample size (each arm)
needed to detect the specified differences between the
placebo and vitamin D arms with at least 80% power for
each outcome.
Previous studies, including our own, suggest that OA
patients have a loss of cartilage volume of 4 to 5% per
year at different joint sites, respectively [42]. Vitamin D
supplementation in doses ranging from 400 to 800 IU/d
increased the serum level of 25-(OH)D by 27 nmol/liter
per year in 7,964 men and women from five studies [43].
We estimate from our published data [15] that this
change will lead to absolute reduction in loss of cartilage
volume by 2.2% at the medial tibial site after vitamin D
supplementation. The sample size that is needed to de-
tect this difference is calculated (Table 2).
We have shown that male OA patients have an in-
crease in medial tibial bone area of 1.6 ± 2.8% per year
[44], and an incidence of knee cartilage defects of 80%
over 2 years [45]. There are no data known to the inves-
tigators about the associations between change in vita-
min D and change in bone area or cartilage defects.
However, healthy subjects have been shown to have an
increase in tibial bone area of 0.7% per year (CD et al.,
unpublished), and an incidence of knee cartilage defects
of 65% over 2 years in older people [46]. Assuming that
changes in cartilage defects and bone area in OA
patients will be suppressed by vitamin D supplementa-
tion to the levels in the healthy subjects, the sample size
needed to detect these differences is given in Table 2.
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20% dropout over the trial) will be sufficient to detect
the differences between treatment groups.
Analysis plan
Statistical primary comparisons for total and subscale
WOMAC scores will be made using a repeated measures
mixed model with terms for treatment, month, center
and the corresponding baseline values as the covariates.
The independent t-tests will be used to compare changes
between groups in quantitative data from baseline to the
end of follow-up. Linear regression (annual changes in
cartilage volume, cartilage defects, bone area and muscle
strength as the dependent variables, and treatment as
the independent variable) and logistic regression (devel-
opment/progression of bone marrow lesions and menis-
cal abnormalities as the dependent variables, treatment
as the independent variable) analyses will be applied in
univariate and multivariate modeling adjusted for age,
sex, body mass index, baseline 25-(OH)D and other dis-
ease status.
In secondary analysis of loss in cartilage volume, the
minimal clinically important differences (MCID) in cartil-
age volume will be calculated [47] and logistic regression
will be used to determine the association between cartilage
loss (>=MCID vs. <MCID) and treatment before and
after adjustment for the covariates described above.
Both intention to treat and per protocol analyses will
be utilized. Per protocol will be defined as achieving a
25-(OH)D level > 60 nmol/liter at month 3. The last ob-
servation carried forward method will be used in the ana-
lysis of all outcomes among patients who made at least
one follow-up visit but did not complete the whole study.
Data integrity and management
All data obtained will be kept strictly confidential and
will be stored electronically on a database with secured
and restricted access. Data transfer will be encrypted and
any information capable of identifying individuals will be
removed.
Withdrawal
If a participant withdraws or is removed from the study,
the reason and date of discontinuation will be recorded.
Any participant who withdraws within year 1 will be
asked to have MRI at the end of year 1; participants with-
drawing after year 1 will be asked to have MRI on leaving
the study.
Monitoring
The trial will be overseen and monitored by a project
manager. The project manager will visit each site to
examine trial procedures to ensure data quality and
compliance with the trial protocol.Discussion
We have proposed this protocol to determine if vitamin
D supplementation can slow disease progression in
patients with knee OA. Vitamin D may have beneficial
effects for the treatment of OA, although there are cur-
rently no recommended guidelines for this approach
[48]. Hence, well-designed randomized controlled trials
are required to test if vitamin D has disease-modifying
and pain-relieving effects. Such studies also need an ap-
propriate follow-up period to capture joint structural
changes using objective measurements over the course
of OA, and this has been incorporated into the design of
the VIDEO study.
Assessing disease-modifying effects on OA requires an
accurate measurement tool that is able to evaluate
improvements in cartilage and joint health. Radiographic
assessment of OA is two-dimensional, lacks sensitivity
for changes over a short period and is highly susceptible
to measurement error through factors such as variation
in joint positioning [49]. MRI allows direct, accurate and
reliable assessment of joint structural changes over time.
These structural changes include cartilage loss, cartilage
defects, increased tibial bone area, subchondral bone
marrow lesions, meniscal tears and meniscal extrusion.
Almost all these structural changes are predictive of
total knee replacement [45,50,51], suggesting they are
clinically relevant. Simultaneously, we will assess change
in knee pain over time using WOMAC as a co-primary
endpoint. Thus, the findings from this study will show
whether vitamin D supplementation has both disease-
modifying and symptom-relieving effects.
As suggested by the 2011 Endocrine Society Clinical
Practice Guideline, all adults aged 50 to 70 years, and
those over 70 years old require at least 600 and 800 IU/d
of vitamin D respectively, to maximize bone health and
muscle function. To raise blood levels of 25-(OH)D
above 75 nmol/liter (the lowest sufficient threshold)
requires at least 1500 to 2000 IU/d of supplemental vita-
min D [52]. Thus, our study design provides a dose of
50,000 IU monthly to achieve serum 25-(OH)D levels
above 60 nmol/liter in all compliant subjects [53]. This
method will be less costly and will be more convenient
than daily treatment. Toxicity is extremely unlikely with
this dose.
Two sub-studies will simultaneously be included in
this trial. Firstly, we will examine the effects of vitamin
D on the function of the deep lumbo-pelvic stabilizing
muscles. Besides implications for low back pain, in
healthy people core muscles have also been implicated
in varying aspects of physical function. The lateral ab-
dominal muscles are theorized to control movement and
provide stability to the trunk for functional activities and
this is supported in a number of studies [54]. Vitamin D
supplementation may have beneficial effects on
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determine the effect of vitamin D supplementation on
blood pressure and aortic stiffness. A recent systematic
review suggested that there is accumulating evidence to
support the hypothesis that vitamin D deficiency contri-
butes to hypertension, and randomized controlled trials
(RCTs) are greatly needed to clarify and to definitively
prove the effect of vitamin D on blood pressure [55].
The VIDEO study aims to be the first to assess this.
In summary, knee OA is a major, but poorly under-
stood, public health problem. Vitamin D deficiency may
play a role in the progression of OA, and based on our
novel preliminary data, the VIDEO study has been
designed to determine whether intervening with vitamin
D supplementation can in fact slow the progression of
this disease and relieve knee pain. If correcting vitamin
D deficiency can reduce rates of cartilage loss to lower
levels as seen in older people without OA, it will signifi-
cantly prolong the time it takes to reach end-stage OA
eventually requiring joint replacement. This suggests
great potential for substantial cost savings through
reductions in joint replacement surgery, as well as po-
tential for great improvements in the quality of life for
people with OA. The success of this study will provide
scientific evidence for using a cost-effective and innova-
tive approach to addressing this clinically significant
problem and will lend itself to an easy public health
intervention.
Trial status
Upon submission, VIDEO study is in the process of
patient recruitment.
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